Clinical Trial Update: Genetic Expression and Prediction of Response to Neoadjuvant Docetaxel or Doxorubicin in Locally Advanced Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 study evaluating genetic predictors of response to neoadjuvant docetaxel or doxorubicin in locally advanced breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Doxorubicin (doxorubicin)

Snippet

Sponsor: Hospital San Carlos, Madrid | Conditions: Breast Cancer | Phase 2 | Status: COMPLETED